

## **CURRICULUM VITAE**

**JUAN C. SALAZAR, MD, MPH, FAAP**  
**ASSOCIATE PROFESSOR OF PEDIATRICS**  
**DIRECTOR, DIVISION OF PEDIATRIC INFECTIOUS DISEASES**  
**UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE/CONNECTICUT**  
**CHILDREN'S MEDICAL CENTER**

### **EDUCATION:**

1980-1986 Medical School (6 year program), Universidad Javeriana, Bogotá, Colombia  
1983 Brown University School of Medicine, medical student exchange program (June-Dec 83'), Providence, Rhode Island  
1988-1991 Pediatric Residency, University of Connecticut Pediatric Residency Program, Farmington, Connecticut  
1991-1992 Chief Resident in Pediatrics, University of Connecticut Pediatric Residency Program, Farmington, Connecticut  
1992-1995 Fellowship, Pediatric Infectious Diseases, University of Minnesota Medical School, Minneapolis, Minnesota  
1993-1995 Master's in Public Health (MPH) in Epidemiology (October 95'), University of Minnesota School of Public Health, Minneapolis, Minnesota

### **PAST WORK EXPERIENCE AND ACADEMIC AFFILIATION:**

1986- 1987 Staff Physician, Clínica Infantil Colsubsidio (Children's Hospital), Bogotá, Colombia  
7/ 1991- 6/1992 Instructor in Pediatrics, Department of Pediatrics (during chief residency), University of Connecticut School of Medicine, Farmington, Connecticut.  
July-Dec, 1995 Post Doctoral Research Associate, Department of Pediatrics, Otitis Media Research Center, University of Minnesota, Minneapolis, Minnesota.  
1/1996- 10/1998 Chief, Pediatric Infectious Diseases Section and Chief, Quality Assurance Office, Fundación, Clínica Valle del Lili, Cali, Colombia.  
10/1998- 3/2005 Assistant Professor of Pediatrics, University of Connecticut's Department of Pediatrics, Division of Pediatric Infectious Diseases.  
2007-08 Trinity College, Health Fellows Principal Advisor, Hartford, CT.

## **CURRENT JOB TITLES AND ACADEMIC AFFILIATIONS**

10/1998 to date	Director Pediatric and Youth HIV Program, Connecticut Children's Medical Center
09/2004 to date	Adjunct Assistant Professor of Pharmacy Practice, University of Connecticut School of Pharmacy.
3/2005 to date	Associate Professor of Pediatrics, University of Connecticut's Department of Pediatrics, Division of Pediatric Infectious Diseases.
12/2006 to date	Major Advisor for the Graduate Program in Public Health, University of Connecticut Health Center.
10/2008 to date	Director, Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Connecticut School of Medicine.

## **PROFESSIONAL SOCIETIES and BOARD QUALIFICATIONS:**

1988	Passed ECFMG examination
1991	Passed FLEX examination
1988 to date	Fellow American Academy of Pediatrics (FAAP), Member ID Section.
1989 – 2000	Member of the American Medical Association (AMA)
1992 to date	Board Certified in Pediatrics (Recertified in July 2000 and December 2006)
1996 - 1997	President, Colombian Infectious Diseases Society, South Western Chapter
1997 - 1998	Treasurer, Colombian Infectious Disease Society (National)
1997 to date	Board Certified in Pediatric Infectious Diseases (Recertified in Nov 2004)
1998 to date	Member of the Hartford County Medical Association
1998 to date	Member of the Connecticut State Medical Association
2001 to date	Member of the Infectious Disease Society of America (IDSA)
2002 to date	Member of the HIV Medical Association (HIVMA)
2005 to date	Member of the Pediatric Infectious Diseases Society of America (PIDS)
2005 to date	Member of the American Society for Microbiology (ASM)
2006 to date	Member of the International AIDS Society (IAS)
2008 to date	Member of the International Innate Immunity and Endotoxin Society

## **HONORS:**

1988-91	Excellence in Patient Care by a Pediatric Resident, Hartford Hospital, Connecticut, U.S.A.
---------	--

- 1990-91 Role Model in Teaching and Patient Care 1990-91, University of Connecticut, Dept of Pediatrics
- 1994-95 John B. Hawley Award for Health Promotion Research (University of Minnesota, School of Public Health)
- 1995 Best scientific presentation - Northwest Pediatric Society fall meeting- 10/95.
- 1998 Consultant for WHO – WHO model prescribing information. Member of the task force that developed and wrote “Drugs used in the treatment of Streptococcal pharyngitis and prevention of rheumatic fever. Geneva, 1998 – WHO/EDM/PAR/99.1”
- 2004 Medalla al Mérito Académico (Medal for Academic Merit), presented by the Corporación de Lucha Contra el SIDA (Corporation for the Fight Against AIDS), Cali, Colombia, March 31, 2004
- 2004 McNeill Spot Teaching Award for excellence in teaching: Connecticut Children’s Medical Center Pediatric Residency Program, June, 2004
- 2004-09 Listed in Hartford Magazine’s Best Doctors in the Greater Hartford Area (2004-2010). Listed in the 2004-2005 “Guide to American Top Pediatricians”, awarded by the Consumers’ Research Council of America, Washington D.C. Listed in the 2005-09 Best Doctors in America database (Pediatrics). Listed in Marquis Who’sWho in Medicine and Health Care, 2006-2007
- 2007 Featured investigator in the American Society of Microbiology Minority Microbiology Mentor Newsletter - October 2007
- 2008 Regional Advocacy for Vaccination of Children Award, Presented by the Merck Vaccine Division, August, 2008
- 2009 Appointed to the Special Emphasis Panel/Scientific Review Group 2009/10 ZRG1 ICP2-B (51): Fogarty Institute, National Institutes of Health.
- 2010 Elected to the Board of Directors of the Child Health Institute of Connecticut and the Children’s Fund of Connecticut.

### **RESEARCH AND SERVICE GRANT AWARDS:**

#### **COMPLETED RESEARCH AWARDS**

- Principal investigator (PI) - Pediatric Clinical Trials Group (sub-unit 7303 and 7394) (multiple protocols) – Western New England ACTU (WNEACTU) from University of Massachusetts School of Medicine – (6/30/99 - 7/1/02).
- PI- Competitive renewal WNEACTU – sub-units 7303 and 7304, from University of Massachusetts School of Medicine. (08/01/02 – 11/31/07)
- PI- Donaghue Foundation: Erythema Migrans: Immunologic window to Lyme Disease - (1/1/01-3/31/06).

- Program Director (PD)- Hartford Foundation for the Public Giving, Through Connecticut Primary Care Association(CPCA) (1999-2002)
- PI: Arrison Research Fund, Through Connecticut Children’s Medical Center 2006-07, Direct amount per year \$ 21,600.
- PI- Immunity in Early Syphilis: Pathway to HIV Co-Infection. (1 K23 AI062439), Career Mentored Clinician Researcher Award (NIAID), July 1/05 – July 31/2009. Direct amount per year /\$145,000
- PI: Connecticut Children’s Medical Center (Research support grant), 2007-09, direct amount per year \$ 96,000.
- PI: Innate Immunity in Secondary Syphilis. (RO-3), FIRCA, NIH, (2008-2010), direct amount, \$ 96,000
- Co-PI Innate Immunity in Secondary Syphilis (PI Dr. Adriana Cruz, CIDEIM, Colombia). 2008-2010, Colciencias Grant. Colombian National Institute of Sciences. Direct Costs (+/- \$200,000 USD based on exchange rate)
- Co-PI (PI Francisco Sylvester) Osteoblasts: Immune Responses in Pediatric Inflammatory Bowel Disease University of Connecticut, Storrs and Regional Campus Incentive Grants (“UCIG”), November 2008-January 2010. Total costs \$ 50,000.
- PI: Connecticut Children’s Medical Center (Research support grant), 2009-2010, direct costs \$286,400. Innate Immune Responses to *Borrelia burgdorferi*.

### **COMPLETED SERVICE AWARDS**

- Project Director (PD)- Ryan White Title II, Through Connecticut Primary Care Association (1999-2010).
- PD- Ryan White Title I (Part A) – Through City of Hartford, CT (1999-2011)
- PD- Ryan White Title IV (Part D), Through Connecticut Primary Care Association (1999-2010)
- PD: Hartford Foundation for the Public Giving (2007-2008), direct amount, \$34,156
- PD. Red Ribbon Foundation (2007-2008), direct amount, \$25,000.

### **COMPLETED INDUSTRY PROTOCOLS**

- Co-Investigator (CI)- Augmentin 40/10 (SKB) – University of Minnesota 1995
- CI Merck Heptavalent Pneumococcal Conjugate Vaccine trial (Merck) – University of Minnesota 1994-1996
- CI Immune response to pneumococcal polysaccharide vaccine (Merck) – University of Minnesota 1995

- CI Reactogenicity of attenuated Varicella vaccine (SKB) – Fundación Valle del Lili, Cali, Colombia 1998
- PI Linezolid Pediatric M/1260/0082 (Pharmacia-Upjohn) – CCMC 2001
- PI Azithromycin vs. Augmentin in children with recurrent AOM – (Pfizer) CCMC 2001.
- PI Azithromycin vs. Amoxicillin in children with AOM A0661091 (Pfizer) CMCM 2003.
- PI Linezolid for Pediatric VRE infections (Pfizer-Pharmacia) – CCMC 2003-2004.
- PI Azithromycin SR vs. Augmentin in children with otitis media (Pfizer) – CCMC 03-04.
- PI TMC114-C226, “Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited or no treatment options” – CCMC 2006

### **CURRENT SERVICE GRANTS**

- PD- Ryan White Part B, Through State of Connecticut (7/1/10 – 6/30/11), Direct amount per year \$ 95,550
- PD- Ryan White Part A, Through State of Connecticut (3/1/11 – 2/28/12), Direct amount per year \$ 135,000
- PD- Ryan White Part D, Through Connecticut Primary Care Association (08/01/09 – 07/31/10), Direct amount per yr/ \$75,288
- PD: Secondary Prevention for HIV infected Youth. State of Connecticut Department of Public Health, 2008-2011, direct amount per year: \$ 68,000
- PD. Red Ribbon Foundation (2010-2011), HIV prevention grant: direct amount, \$10,000.

### **CURRENT RESEARCH AWARDS**

- PI: Connecticut Children’s Medical Center (Research support grant), 2011 direct costs \$50,000 (year). Secondary syphilis in Cali, Colombia.
- PI: R56 AI090166 NIAID (09/27/10 – 08/31/11) Direct Costs:\$ 293,038 (year) Phagosomal signals shape inflammatory responses to *Borrelia burgdorferi*.
- PI: R0-1 AI090166 NIAID (07/1/11- 6/30/16) Phagosomal signals shape inflammatory responses to *Borrelia burgdorferi*. Received favorable score (17 - 9<sup>th</sup> percentile), scheduled to start 7/1/2011.

### **CONSULTATIONS AND COMMITTEES:**

- Secretary-Treasurer, University of Connecticut Pediatric Alumni Club, 1999 to date.
- Member, Pharmacy and Therapeutics Committee, CCMC, 1999 to 2004.
- Member of the University of Connecticut Health Center’s AIDS Task Force, 1999 to date.

- Chair, Clinical Trials Council, Connecticut Children's Medical Center, 2000 - January 2004.
- Member of Board for the Claire Nsenga Foundation (Non-profit Uganda HIV relief organization) 2003-2006.
- Member of the Biosafety Committee at St. Francis Hospital and Medical Center, Nov 04-11
- Appointed member of the Clinical Research Council, Connecticut Children's Medical Center. 2011
- Member of the Editorial Boards for: Journal of the Colombian Infectious Disease Society (Infectio: 2002-08) and Journal of the Escuela de Medicina del Hospital Militar (Colombia) (Revista Med: 2005-08).
- Reviewer for the following journals: Pediatrics, American Journal of Pediatric Drugs, Journal of Immunology, Journal of Social Science & Medicine, Journal of Pediatric Infectious Diseases, Microbes and Infection, Archives of Pediatrics and Adolescent Medicine, Journal of Sexually Transmitted Infections, Journal of Pediatrics, Clinical and Vaccine Immunology, Infection and Immunity, Journal of Clinical Microbiology and the Journal of the Pan American Health Association.

#### **PUBLICATIONS IN PEER REVIEWED JOURNALS**

1. **Salazar JC**, Gerber MA, and Goff CW: Long-term outcome of Lyme disease in children given early treatment. Journal of Pediatrics; 122(4): 591-593, 1993.
2. **Salazar JC**, Toro-Salazar OH, and Kaplan EL: Infective endocarditis in children, "An evaluation at the close of the twentieth century". Intercontinental Cardiology, 2(1): 7-15, 1993
3. **Salazar JC**, and Ferrieri PF. Review of the new guidelines for the diagnosis of rheumatic fever. Infections in Medicine, 11(11): 717-722, 1994.
4. **Salazar JC**, Londoño LJ, Liebeler C, Trujillo F, Meier J, and Giebink GS. Pneumococcal seroepidemiologic study of Colombian and Minnesota children. Pediatric Infectious Diseases Journal. 14(11): 1001-1003. 1995
5. **Salazar JC**, Bloom KE, Hostetter MK, Leonardi CL. Drug resistant tuberculosis verrucosa cutis in a South East Asian teenager. Pediatric Infectious Diseases Journal 15(9), 834-836, 1996.
6. **Salazar JC**, Daly KA, Giebink GS, Lindgren BR, Liebeler CL, Meland M, and Le CT. Low cord blood pneumococcal Immunoglobulin G (IgG) antibodies predict early onset otitis media in infancy. American Journal of Epidemiology, 145(11), 1048-1056, 1997.
7. Jones RA, **Salazar JC**, Pfaller MA and Doern GV. Multi-Center evaluation of antimicrobial resistance to six broad-spectrum B-lactams in Colombia using the Etest method. Diagn Microbiol Infect Dis, 29, 1-8, 1997.
8. Pfaller MA, Jones RN, Doern GV, **Salazar JC**. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta lactams in Colombia: comparison of data from 1997

- and 1998 using the Etest method. The Colombian Antimicrobial Comparison Resistance Study Group. Diagn Microbiol Infect Dis. 35(3): 235-241, 1999
9. Crespo MP, Velez JD, Castañeda CR, Hoyos F, Lopez ML, and **Salazar JC**. Aislamiento de *Listeria monocytogenes* en un hospital de tercer nivel. Colombia Médica. Vol 30 (2), 89-98, 1999.
  10. Sellati TJ, Waldrop SL, **Salazar, JC**, Bergstresser PR, Picker LJ, and Radolf JD. The cutaneous response in humans to *Treponema pallidum* lipoprotein analogues involves cellular elements of both innate and adaptive immunity, J Immunol, 166:4131-4140, 2001...
  11. Zervas SJ, Zemel LS, Romness MJ, Kaplan EL and **Salazar JC**. *Streptococcus pyogenes* pyomyositis. Pediatr Infect Dis J. 21:166-168 2002.
  12. Acosta-Glynn C, Fernandez NL, Neal R, and **Salazar J**. Hartford Youth HIV Identification and Linkage to Care (H.Y.H.I.L.) XIV International AIDS Conference. Extended Abstract C708S8854, Moduzzi Editore S.p.A. 97-101, 2002.
  13. **Salazar JC**, Hazlett KRO, Radolf JR. The immune response to infection with *Treponema pallidum*, the stealth pathogen. Microbes and Infection, 4 (11), 1133-1140, 2002.
  14. Feder HM, Roberts JC, **Salazar JC**, Leopold HB, Toro-Salazar O. HACEK Endocarditis in Infants and Children: Two Cases and Review of the Literature. Pediatr Infect Dis J, 22(6):557-562, 2003.
  15. **Salazar JC**, Pope CD, Sellati TJ, Feder HM, Kiely TG, Dardick KR, Buckman RL, Moore MW, Caimano MJ, Pope JG, Krause PJ, Radolf JR and The Lyme Disease Network. Co-evolution of Innate and Adaptive Immunity in Skin and Peripheral Blood of Patients with Erythema Migrans. J Immunology, 2003, 171:2660-2670.
  16. **Salazar JC**. Pediatric Clinical Trial Experience: Government, Child, Parent and Physician's Perspective, Pediatr Infect Dis J. 2003;22(12):1124-1127.
  17. Berrien VM, **Salazar JC**, Reynolds E. and McKay K. Adherence to Antiretroviral Therapy in HIV-Infected Pediatric Patients Improves with Home-Based Intensive Nursing Intervention. AIDS Patient Care and STDs. 2004, 18(6):355-364.
  18. Ellis JM, Reilly JC, and **Salazar JC**. Influenza vaccination for the pediatric patient: A focus on the new intranasal, cold-adapted, live attenuated vaccine. J Pediatr Pharmacol Ther, 2004, 9(2), 104-109.
  19. **Salazar JC**, Pope CD, Moore MW, Pope J, Kiely TG and Radolf JD. Lipoprotein-dependent and -independent immune response to spirochetal infection. Clin. Diag. Lab. Immunol. 12, 949-958, 2005.
  20. Smith-Slatas C, Bourque MD, and **Salazar JC**. *Clostridium septicum* Infections in Children: A Case Report and Review of the Literature. Experience and Reason. Pediatrics. 117(4), e796-e805, 2006.
  21. Raju M, **Salazar JC**, Leopold H, and Krause PJ. Atovaquone and Azithromycin Treatment for Babesiosis in an Infant. Pediatr Infect Dis J. 2007 Feb; 26(2):181-183.

22. **Salazar JC**, Cruz A, Pope C, Valderrama L, Trujillo R, Saravia NG, and Radolf JD. *Treponema pallidum* elicits Innate and Adaptive Cellular Immune Responses in Skin and Blood during Secondary Syphilis: A Flow Cytometric Analysis. JID, 2007; 195(6):879-87
23. Moore, MW, Cruz, AR, LaVake, CJ, Marzo, AL, Eggers, CH, **Salazar, JC**, and Radolf, JD, Phagocytosis of *Borrelia burgdorferi* and *Treponema pallidum* potentiates innate immune activation and induces IFN- $\gamma$  production. Infection and Immunity, 2007 Apr; 75(4):2046-62.
24. Ellis JM, Rivera L, Reyes G, Castillo F, Castillo P, Tejada M and **Salazar JC**. Cefepime Cerebrospinal Concentrations in Neonatal Bacterial Meningitis. The Annals of Pharmacotherapy, 41(7), 900-901, 2007
25. **Salazar JC**, Rathi A, Michael NL, Radolf, JD, Jagodzinski LL. Assessment of the Kinetics of *Treponema pallidum* Dissemination into Blood and Tissues in Experimental Syphilis by Real-Time Quantitative PCR. Infection and Immunity, 75(6), 2954-2958, 2007.
26. St. Germain RM, Sevket Y, Wells L, Ellis JM, **Salazar JC**. Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV infected adolescent. AIDS Patient Care and STDs, 21(6), 373-77, 2007.
27. Cruz AR, Moore MW, LaVake CJ, Eggers CH, **Salazar JC**, Radolf JD. Phagocytosis of *Borrelia burgdorferi*, the Lyme disease spirochete, potentiates immune activation and induces apoptosis in human monocytes. Infection and Immunity, 76(1):56-70, 2008
28. **Salazar JC**, Cahn P, Yogev R, Della Negra M, Castelli-Gattinara G, Fortuny C, Flynn P, Giaquinto C, Capparelli EV, Fenton T, Mikl J, Jelaska A, for the PACTG 1051/BI study team. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS, 22: 2008
29. Coulter J, Giroto J, **Salazar JC**, Tipranavir a new protease inhibitor for the pediatric population. Expert Rev Anti Infect Ther. 2008 Dec;6(6):797-803.
30. **Salazar JC**, Duhnam-Ems S, LaVake CJ, et al. Activation of human monocytes by live *Borrelia burgdorferi* generates TLR2-dependent and -independent responses which include induction of IFN-beta. PLoS Pathog 2009 May; 5(5):e1000444.
31. Lomotey CL, Lewis J, Gebrian B, Bourdeau R, Dickhaus K, **Salazar JC**. Maternal and Congenital Syphilis in Rural Haiti. Pan Am J Public Health, 26(3), 197-202, 2009.
32. Feder Jr. HM and **Salazar JC**. A clinical review of 105 patients with PFAPA (A periodic fever syndrome). Acta Paediatrica, 2009, September.
33. Kanev P, **Salazar JC**. Unusual CNS infection from a subtorcular dermal sinus. Acta Paediatr. 2009 Nov 12
34. Sahay B, Patsey RL, Eggers CH, **Salazar JC**, Radolf JD, Sellati TJ. CD14 signaling restrains chronic inflammation through induction of p38-MAPK/SOCS-dependent tolerance. PLoS Pathog. 2009 Dec;5(12):e1000687.
35. Courter JD; Giroto JE, Lobato MN, Orcutt D; Burke M, Feder HM; Krause PJ, Cohen-Abbo A, **Salazar JC**. Intravenous streptomycin treatment for an infant with tuberculosis meningitis. Accepted for publication in Pharmacotherapy, March, 2010.



36. Cruz AR, Pillay A, Zuluaga AV, Ramirez LG, Duque JE, Aristizabal GE, Fiel-Gan MD, Jaramillo R, Trujillo R, Valencia C, Jagodzinski L, Cox DL, Radolf JD, **Salazar JC**. Secondary syphilis in Cali, Colombia: New concepts in disease pathogenesis. *PLoS Negl Trop Dis*. 2010 May 18;4(5):e690
37. Deville JG, Goldfarb J, Kaplan SL, Equils O, Huang DB, Ang JY, **Salazar JC**. The use of linezolid in the treatment of paediatric patients with infections caused by enterococci including strains resistant to vancomycin. *J Antimicrob Chemother*. 2010 Oct;65(10):2267-70. Epub 2010 Aug 12. PubMed PMID: 20705627.
38. Desrosiers DC, Bearden SW, Mier I Jr, Abney J, Paulley JT, Fetherston JD, **Salazar JC**, Radolf JD, Perry RD. Znu is the predominant zinc importer in *Yersinia pestis* during *in vitro* growth but is not essential for virulence. *Infect Immun*. 2010 Sep 20. [Epub ahead of print] PubMed PMID: 20855510.
39. Cox DL, Luthra A, Dunham-Ems S, Desrosiers DC, **Salazar JC**, Caimano MJ, Radolf JD. Surface immunolabeling and consensus computational framework to identify candidate rare outer membrane proteins of *Treponema pallidum*. *Infect Immun*. 2010 Sep 27. [Epub ahead of print] PubMed PMID: 20876295
40. Cervantes JL, Dunham-Ems SM, La Vake CJ, Petzke MM, Sahay B, Sellati TJ, Radolf JD, **Salazar JC**. Phagosomal signaling by *Borrelia burgdorferi* in human monocytes involves Toll-like receptor (TLR) 2 and TLR8 cooperativity and TLR8-mediated induction of IFN- $\beta$ . *Proc Natl Acad Sci*. 2011 Mar 1;108(9):3683-8. Epub 2011 Feb 14
41. Stojanov S, Lapidus S, Chitkara P, Feder H, **Salazar JC**, Fleisher TA, Brown MR, Edwards KM, Ward MM, Colbert RA, Sun HW, Wood GM, Barham BK, Jones A, Aksentijevich I, Goldbach-Mansky R, Athreya B, Barron KS, Kastner DL. PFAPA syndrome is a disorder of innate immune regulation and Th1 activation responsive to IL-1 blockade. *Proc Natl Acad Sci U S A*. 2011 Apr 8. [Epub ahead of print].
42. Desrosiers DC, Anand A, Luthra A, Dunham-Ems SM, Ledoyt M, Cummings MA, Eshghi A, Cameron CE, Cruz AR, **Salazar JC**, Caimano MJ, Radolf JD. TP0326, a *Treponema pallidum*  $\beta$ -Barrel Assembly Machinery A (BamA) Ortholog and Rare Outer Membrane Protein. *Mol Microbiol*. 2011 Apr 14 [Epub ahead of print].

### **NON PEER REVIEWED PUBLICATIONS**

1. Rosso F, Velez JD, **Salazar JC**, Lopez P, Corral R, Villegas MV, Muñoz J. Guia para el manejo de dengue y sus complicaciones. *Boletín, Servicio Integrado de Enfermedades Infecciosas (SIEI)*, 4(1), 20-22, 1998
2. **Salazar JC**. Uso de corticoides en meningitis bacteriana (Editorial). *Infectio (Journal of the Colombian Infectious Diseases Association)*, 2(1), 2, 1998.
3. Rincón HG, **Salazar JC**, Congote A. El consentimiento informado en la Fundación Clínica Valle del Lili. *Colombia Médica*. Vol 30 (2), 99-101, 1999.

## **BOOKS and BOOK CHAPTERS**

1. Lopez P, Levy A, Caicedo Y, **Salazar JC**, Osorio MA. Consenso para manejo de enfermedades infecciosas en pediatría. Asociación Colombiana de Infectología. Centro Editorial Catorse SCS, Cali, Colombia, 1997
2. **Salazar JC** and Radolf JD. Management of an HIV-positive pregnant woman with a positive VDRL test from an area endemic for Treponema infection. Cohen & Powderly/Infectious Diseases 2e/Chapter 66a, 725 – 727, Elsevier, 2003
3. **Salazar JC**. Antibiotic treatment for streptococcal pharyngitis: Part I: Penicillin first? In: Issues in Infectious Diseases, Vol 3, Streptococcal Pharyngitis, Optimal Management. 112-123. S. Karger AG, Basel, Switzerland, 2004
4. Berrien VM, **Salazar JC**, Reynolds E and McKay K. Section 4, Special Populations: Adherence to Antiretroviral Therapy in HIV-Infected Pediatric Patients Improves with Home-Based Intensive Nursing Intervention. In: Medication Adherence in HIV/AIDS, Jeffrey Laurence, Editor (2004).
5. **Salazar JC**. Management of an HIV-positive pregnant woman with a positive VDRL test from an area endemic for Treponema infection. Cohen & Powderly/Infectious Diseases 3e/Practice Point 23, Elsevier, to be published in March 2010
6. Radolf JD, **Salazar JC**, and Dattwyler RJ, Lyme Disease in Humans, in Borrelia; Molecular Biology, Host Interaction and Pathogenesis. Edited by: D. Scott Samuels and Justin D. Radolf. Caister Academic Press, UK, to be published March 2010.
7. **Salazar JC** and Feder HM, Periodic Fever Syndromes. Chapter 176, in Textbook of Pediatric Dermatology, 3<sup>rd</sup> Edition, Edited by A. Irvine, P. Hoeger and A. Yan, 2011, Blackwell Publishing Ltd.

## **PEER REVIEWED PUBLICATIONS AUTHORSHIP AS PART OF A STUDY GROUP**

1. Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Diedume A, Khoury M, Mendez H, Nachman S, Wiznia A. **Salazar JC in the Pediatric AIDS Clinical Trials Group 377 Study Team**. Nucleoside analogue reverse transcriptase inhibitors plus nevirapine, zidovudine, or zalcitabine for pretreated children infected with HIV type 1. CID 34, 991-1001, 2002.
2. Krause PJ, McKay K, Thompson CA, Sikand VJ, Lentz R, Lepore T, Closter L, Christianson D, Telford SR, Persing D, Radolf J, Spielman A. **Salazar JC, in: the Deer Associated Infection Study Group**. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. CID; 34:1184-1191, 2002.
3. Cunningham CK, Chaix ML, Rekacewicz C, Britoo P, Rouzioux RD, Gelber RD, Dorembaum A, Delfraissy JF, Bazin B, Mofenson L, and Sullivan JL. **Salazar JC in: the Pediatric AIDS Clinical Trials Group 316 Study Team**. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JID, 186:181-8. 2002.

4. Caughan DM, Hughes MD, Seage GR, Selwyn PA, Carey VJ, Gortmaker SL, and Oleske JM. Salazar J in PACTG 219 Team. The prevalence of pain in pediatric HIV/AIDS as reported by participants in the pediatric late outcomes study (PACTG 219). *Pediatrics*, 109(6), 2002.
5. Dorenbaum, A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, ekacewicz C, Delfraissy JF, Cunningham-Schrader B, Mirochnick M and Sullivan JL for the international PACTG 316 team. Salazar JC, in: PACTG 316 Study Team. Two-Dose Intrapartum/Newborn Nevirapine to Standard Antiretroviral Therapy to Reduce Perinatal Human Immunodeficiency Virus type-1 Transmission: *JAMA*, 288(2), 2002
6. Krause PJ, McKay K, Gadabaw J, Christianson D, Closter L, Lepore T, Telford III SR, Sikand V, Ryan R, Persing D, Radolf JD, Spielman A: Salazar JC, in Tick-Borne Infection Study Group. Increasing Health Burden of Human Babesiosis in Endemic Sites. *Am J Trop Med Hyg*, 68(4), 431-436, 2003.
7. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB, and Salazar JC in The Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. *Pediatr Infect Dis J* 22(8): 677-686; 2003
8. Chang-Heok S, Oleske JM, Brady MT, Spector SA, Borkowsky W, Burchett SK, Foca MD, Handelsman E, Jimenez E, Dankner MD: Salazar J, in PACTG 219 Team. Long Term effects of protease inhibitor based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. *The Lancet*, 362, 2045-2051, 2003.
9. DM. Gaughan, MD Hughes, JM Oleske, KM Carol, A Gore, Sharon Nachman: JC Salazar in the Pediatric AIDS Clinical Trials Group 219C Team. Psychiatric Hospitalizations Among Children and Youths With Human Immunodeficiency Virus Infection. *Pediatrics* 113 (6) pp. e544-e551, 2004.
10. Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, Lindsey: Salazar J, in PACTG 219 Team. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. *J Acquir Immune Defic Syndr.* 1; 38(4):480-7. Apr 2005
11. Arguedas A, Empananza P, Schwartz RH, Soley C, Guevara S, de Caprariis PJ, and Espinosa G. Salazar JC, in protocol A0661091 team. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. *PIDJ*, 24(2), 153-161, 2005
12. Abzug MJ, Pelton SI, Song L, Fenton T, et al.; Salazar JC, in PACTG 1024 protocol team. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in HIV infected children receiving HAART. *PIDJ*, 25(10), 920-929, 2006
13. Lindsey JC, Malee KM, Brouwers P, Hughes MD; Salazar J in the PACTG 219C Study Team. Neurodevelopmental Functioning in HIV-Infected Infants and Young Children Before and After the Introduction of Protease Inhibitor-Based Highly Active Antiretroviral Therapy. *Pediatrics* 119 (3) pp. e681-e693, 2007

14. Fiscus SA, Kovacs A, Petch LA, Hu C, Wiznia AA, Mofenson LM, Yogev R, McIntosh K, Pelton SI, Napravnik S, Stanley K, Nachman SA.; Salazar JC in the PACTG 338 group. Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). *AIDS Res Ther.* 6;4:2, 2007
15. Patel K, Hernan MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR. Salazar JC in the Pediatric AIDS Clinical Trials Group 219/219C study team. Long term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: A 10 year follow-up study. *CID* 2008;46, 507-515.
16. Van Dyke RB, Wang L, Williams PL; Salazar JC in the Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis.* 2008 Dec 1;198(11):1599-608
17. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR 3rd; Salazar JC in International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. *AIDS.* 2009 Sep 10;23(14):1893-901.
18. Nachman SA, Chernoff M, Gona P, Van Dyke RB, Dankner WM, Seage GR 3rd, Oleske J, Williams PL; Salazar JC in PACTG 219C Team. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. *Arch Pediatr Adolesc Med.* 2009 Feb;163(2):164-71. Erratum in: *Arch Pediatr Adolesc Med.* 2009 Apr;163(4):364.

### **SCIENTIFIC PRESENTATIONS**

1. Salazar JC, Gerber MA, and Goff CW: Long Term Outcome of Children Treated for Early Lyme Disease. Oral presentation at the Society for Pediatric Research, Baltimore, Maryland. May 1992.
2. Salazar JC, Hohenboken MJ, Londoño LJ, Liebeler CL, Meier J, and Giebink GS. Pneumococcal Vaccine Implications From Seroepidemiologic Study of Colombian Children. Poster # 239 presented at the Infectious Disease Society of America meeting Orlando, Florida, 1994.
3. Salazar, JC, Londoño, LJ, Liebeler CL, Trujillo FA, Giebink GS. Conjugate pneumococcal vaccine strategies from seroepidemiologic study of Colombian children. Oral presentation 0-39.393. VII Panamerican Infectious Disease Congress, Cartagena, Colombia, May 28-31, 1995.
4. Salazar JC, Daly KA, Muggli M, Liebeler C, Lindgren B, and Giebink GS. Type 14 anti pneumococcal antibodies predict early onset otitis media. Oral presentation at the International Conference on Otitis Media Pathogenesis. Fort Lauderdale, Florida, June 1995.
5. Castañeda CR, Velez JD, Salazar JC. Epidemia de *S. pyogenes* en un hospital de tercer nivel. Presented at the Congreso Colombiano de Medicina Interna, Bogotá, Colombia. October 1996.

6. Hoyos F, Salazar JC, Velez JD. Factores de riesgo en infección nosocomial en operaciones cardiovasculares. Presented at the Congreso Colombiano de Medicina Interna, Octubre 1996. Santa Fe de Bogotá.
7. Lozano F, Caicedo Y, Jaramillo AC, Mattar S, Salazar JC, Velez LA, Villanueva G, Jimenez G, Merino N, Villegas MV, Mejia GI, Jones RN, Pfaller MA. Multi-Center evaluation of antimicrobial resistance to six broad-spectrum B-lactams in Colombia using the Etest method. Presented at the 1997 ICAAC, Toronto, Canada.
8. Crespo MP, Castaneda CR, Velez JD, Salazar JC. Listeriosis in a tertiary care center in Colombia. Presented at the 1998 ICAAC, San Diego, California.
9. Crespo MP, Castañeda MP, Velez JD, Salazar JC. Epidemiología del *S. pneumoniae* en la Fundación Valle del Lili, Cali, Colombia. Presented at the IV Colombian Infectious Diseases Association Meeting, Cartagena, Colombia, June, 1999.
10. Reynolds E, Berrien V, Acosta-Glynn C, and Salazar JC. Home based, intense, nursing intervention trial improves adherence to HAART in HIV infected children (poster # 275). Presented at the 2001 Pediatric Academic Societies Meeting, Baltimore Maryland, April 2001
11. Salazar JC, Sellati TJ, Kiely T, Feder HM, Krause PJ, Dardick KR, Buckman RL, Warren CW, KJ Pellegrino JL, Moynihan NT and Radolf JD. Erythema Migrans Immunologic Window to Lyme Disease (poster 601). Presented at the 39<sup>th</sup>, Infectious Diseases Society of America, San Francisco, California, October 25-28, 2001.
12. Acosta-Glynn CI, Fernandez NL, Neil R, and Salazar JC. Hartford (Connecticut/USA) youth HIV linkage to care (HYHIL). ThPeG8356 Poster presentation at the XIII International AIDS Conference, Barcelona, Spain. July 11, 2002
13. Weeks B, Toro-Salazar OH, and Salazar JC. Kawasaki disease at Connecticut Children's Medical Center. Presented at the 40<sup>th</sup> IDSA meeting in Chicago, Illinois (October 24 -27<sup>th</sup>), 2002.
14. Ellis JM, Rivera L, Reyes G, Castillo F, Castillo P, Tejada M and Salazar JC. Cefepime in Neonatal Meningitis. Poster presentation at the 2004 PAS and ESPR Annual Meetings. San Francisco, CA, May 1-5
15. Natt BC and Salazar JC. Variations in Pediatric Tuberculosis Screening in Connecticut Schools. Presented oral symposia at the Easter Society for Pediatric Research Meeting, Greenwich Connecticut, March, 2005 and for poster presentation at the 2005 Academic Pediatric Societies Annual Meeting, Washington D.C. May 14-17<sup>th</sup>
16. Salazar JC, Cruz A, Trujillo R, Pope C, Obando AM, Sombredero A, Saravia N and Radolf JD. Immunity in early syphilis: pathway to HIV co-infection. Poster presentation at the July, 2005, ISSTD meeting, Amsterdam, The Netherlands.
17. Rathi A, Cooley J, Salazar J, Radolf J, Spooner K, Michael N, and Jagodzinski L: Real-Time PCR Detection of *Treponema pallidum*: A Time Course Correlation with Antibody Response. Presented at the CHI Nucleic Acid Based Technologies: Applications Amplified Meeting. June 27-28th, 2005 Baltimore, Maryland.

18. Lucini SE, Ellis JM and Salazar JC. Adverse Effects of Protease Inhibitors in Pediatric and Adolescent Patients. Poster presentation at American Society for Health System Pharmacists Midyear Clinical Meeting, Las Vegas Dec 4-8, 2005.
19. Sabo JP, Cahn P, Della Negra M, Castelli-Gattinara G, Fortuny C, Yogeve R, Salazar J, Chan-Loi Yong CL, Mikl J, and Jelaska A. Population Pharmacokinetic (PK) Assessment of Systemic Steady-State Tipranavir (TPV) Concentrations for HIV+ Pediatric Patients Administered Tipranavir/Ritonavir (TPV/r) 290/115 mg/m<sup>2</sup> and 375/150 mg/m<sup>2</sup> BID (BI 1182.14 and PACTG 1051 Study Team). Poster presentation (# 687) at the 2006, CROI meeting, Denver, Colorado, February 2006.
20. Salazar J., Cahn P., Della Negra M., Castelli-Gattinara G., Fortuny C., Flynn P., Giaquinto C., Yogeve R., Capparelli E., Fenton T., Mikl J., Jelaska A., PACTG 1051. Efficacy and safety results of 48 weeks of treatment with APTIVUS oral solution co-administered with low dose ritonavir (APTIVUS/r) in children and teenagers (Phase I/IIa study). Oral presentation at the International AIDS Meeting, Toronto, Canada, August, 2006.
21. St. Germain RM, Lucini SE, Ellis JM., Coleman CI., and Salazar JC. Dyslipidemia differences among protease inhibitors (PIs) in children. Poster presentation (#187). American College of Clinical Pharmacy, 2006 Annual Meeting, Oct 26-29, 2006, St. Louis, MO
22. Salazar JC, Cahn P, Della Negra M, Castelli-Gattinara G, Fortuny G, Flynn P, Yogeve R, Ruan PK, Mikl J, Jelaska A. Predictors of response to TPV/r in pediatric patients: results of PACTG1051/BI1182.14 (Poster R-130). Poster presentation at the 2007, Conference on Retroviruses (CROI), February, 2007 Los Angeles, CA.
23. Salazar JC, Aristizabal G, Pulido C, Duque J. Congenital syphilis epidemiology in Cali, Colombia (Poster 684). Accepted for poster presentation at the 2007 ISSTD in Seattle, WA. July, 2007.
24. Salazar JC. The immunologic consequences of stealth pathogenicity. Presented at the Yearly University of Connecticut Health Center, Immunology Program Retreat. Avery Point, New London, Connecticut, October 12<sup>th</sup>, 2007.
25. Lapidus S, Chitkara P, Feder F, Salazar JC, Aksentijevich I, Barham B, A Balu, Barron K, Kastner D, Stojanov S. Unraveling the Pathogenesis of Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) Syndrome: An Immunological Approach. Presented at The Fifth International Congress on Familial Mediterranean Fever and Systemic Auto-inflammatory Diseases Rome, April 4 -8, 2008.
26. O'Boyle J, Wells L, Salazar JC. Enhanced Awareness, Education and Prevention of HIV Infection and STDs in North Central Connecticut Public Schools. Presented at the Trinity College Health Fellows Research Meeting, April 29, 2008, Hartford, CT.
27. Salazar, JC, Cahn P, Giaquinto C, Yogeve R, Mikl J, Jelaska A, for the PACTG1051 study team. Efficacy and safety profile of APTIVUS oral solution or capsules co-administered with low dose ritonavir (APTIVUS/r) in treatment experienced children and teenagers after two years of treatment (Phase I/IIa study). Accepted for Poster presentation at the 2008, Mexico City, International AIDS Society Meeting.

28. Salazar JC, Lavake C, Cruz AR, Krueger W, Olson C, Moore M, Anguita J and Radolf JD. *Borrelia burgdorferi* elicits phagocytosis dependent, non TLR1/2 or TLR5 mediated, inflammatory signals in human monocytes. Accepted for poster presentation at the 10<sup>th</sup> Biennial Meeting of the International Endotoxin and Innate Immunity Society, Edinburgh University, Scotland, United Kingdom, July, 2008.
29. Sivia Lapidus, et al. Salazar JC. Immune Dysregulation in Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) Syndrome Involving the Gamma Interferon-inducible Protein 10 (IP-10), a Cytokine Chemotactic for T Lymphocytes. Presented at the 2008 ACR/ARHP Annual Scientific Meeting in San Francisco, CA
30. Cruz AR, Ramirez L, Zuluaga AV, Navas A, Valderrama L, Radolf JD and Salazar JC. Secondary Syphilis Circulating Innate Immune Cell Dysfunction. Poster Presentation at the ICAAC/IDSA Meeting. Washington, D.C. October, 2008
31. Cruz AR, Aristizabal GE, Salazar JC, Public Health Strategies to Control Congenital Syphilis in Cali, Colombia. Presented at the July 2009 ISSTD/BASHH Meeting, London, England (poster # 1582672)
32. Salazar JC, Cervantes JL, La-Vake C, Dunham ES, Petzke MM, and Radolf JR. Phagosomal signaling by Bb induces diverse pro- and anti-inflammatory responses in human monocytes through a cooperative interaction between TLR1/2 and TLR8. Accepted for poster presentation at the Gordon Conference for Spirochetal Research, Ventura Beach, CA, January 2010.
33. Cruz AR, Pillay A, La-Vake C, Valencia C, Ramirez L, Radolf JD, and Salazar JC. Systemic innate immune responses during untreated secondary syphilis. Accepted for oral presentation at the Gordon Conference for Spirochetal Research, Ventura Beach, CA, January 2010.
34. Linezolid use in the treatment of vancomycin-resistant Enterococcus in paediatric patients (Abstr. 1251) J. Deville, J. Goldfarb, S. Kaplan, O. Equils, D. Huang\*, J. Ang, J. C. Salazar (Los Angeles, Cleveland, Houston, New York, Detroit, Hartford, US). Accepted for poster presentation at the 20<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases. Vienna from 10 – 13 April 2010.

## **INVITED LECTURSHIPS (1998 to date)**

### Hospital Grand Rounds/ Other Hospital Based CME Events

1. Sinusitis, rational approach to diagnosis and treatment. St. Francis Medical Center's Pediatric Grand Rounds, December, Hartford, CT, November – 1998
2. Hepatitis, A-H, Pediatric Grand Rounds, Manchester Memorial Hospital, Manchester, Connecticut, May - 1999.
3. Otitis Media- Review of the new guidelines – Pediatric Grand Rounds – William Backus Hospital, Norwich, Connecticut - August, 1999
4. Featured Speaker, Manchester Memorial Hospital, Current Trends in Adolescent HIV Treatment and Prevention (CME accredited). Sponsored by the Connecticut AIDS Health Education Consortium (AHEC). May 21<sup>st</sup>, 2002.
5. Guest speaker, Pediatric Practices Today (Nursing Conference). Pediatric AIDS, Monday May 6<sup>th</sup>, 2002, CCMC, Hartford, CT.
6. ENT Grand Rounds and Journal Club invited speaker (CME accredited). University of Connecticut ENT Residency Program. Update on pediatric HIV. June, 2002
7. Guest speaker, Pediatric Practices Today (Nursing Conference). Immunizations in Pediatrics, Monday May 5<sup>th</sup>, 2003, Hartford Connecticut.
8. Pediatric Grand Rounds (CME accredited), Backus Hospital, January 9, 2003. Curving Resistance in Otitis Media Treatment.
9. Invited Speaker. Innate and Adaptive Immunity in Erythema Migrans Patients. CME Research Conference, University of Connecticut Health Center Intercity ID Rounds, June 17, 2003
10. Immunodeficiency in children – ENT grand rounds invited speaker (CME accredited). University of Connecticut ENT Residency Program. June 18, 2003.
11. Pediatric Grand Rounds – Backus Hospital (Pediatric Pneumonia), November 15, 2003
12. Invited Speaker: Pox, the mysteries of syphilis. CCMC research conversations. November 19, 2003.
13. Guest speaker, Grand Rounds, Otitis Media, Treatment Update, Middlesex Hospital Grand Rounds, Middletown, Connecticut, January 9, 2004.
14. Otitis Media- Current Treatment Guidelines. Pediatric Grand Rounds (CME accredited), Bridgeport Hospital, September 10, 2003.
15. Pediatric Pneumonia, Pediatric Grand Rounds, William Backus Hospital, Norwich Connecticut, October 9, 2003.
16. Invited speaker. Lyme Disease, Road to Syphilis Pathogenesis, CCMC, Research Conversations, Jan 20, 2004.
17. Invited Speaker. Update on cephalosporins, NICU CME meeting, John Dempsey Hospital, May, 2004.



18. Featured Speaker, “Pathways in Research” – Sponsored by the Donaghue Foundation, Lyme Disease Pathogenesis, University of Connecticut Health Center. June 29, 2004.
19. Update 2004 – Otitis Media. Grand Rounds Backus Hospital. Norwich, CT, October 21, 2004.
20. Guest Speaker, Adolescent HIV – CME event sponsored by CAETC (Connecticut AIDS Education and Training Center), Hawthorne Inn, Berlin, Connecticut - January 24, 2005
21. Guest speaker, Pediatric Practices Today, CCMC Nursing Department. “Primary Immunodeficiency Disorders”. May 11, 2005, Hartford, CT.
22. Pediatric HIV. ENT grand rounds, CCMC, May 2005.
23. Syphilis and HIV: diabolic combination. CCMC Research Conversations. May 19, 2005.
24. Perinatal HIV: 25 years. CCMC’s Grand Rounds. May 24, 2005.
25. Varicella Vaccination. Lawrence Memorial Hospital, Pediatric Grand Rounds, June, 2005.
26. Varicella Vaccination. Bristol Hospital, Pediatric Grand Rounds, July 19, 2005.
27. Pediatric Grand Rounds, Backus Hospital, Pediatric HIV 25 years, June 22, 2006.
28. Perinatal HIV: Tale of Two States/ CT and NY. CCMC Pediatric Grand Rounds, September 12<sup>th</sup>, 2006.
29. Intercity ID Rounds: CME event. Guest speaker – Journal Club, September 19, 2006, University of Connecticut Health Center.
30. Pediatric Grand Rounds: Bridgeport Hospital. Update on treatment of respiratory infections in children. November 29, 2006.
31. Perinatal HIV: 25 years. Neonatal Fellows CME conference, UCHC, November 29, 2006.
32. The Lowell P. Weicker, Jr., General Clinical Research Center (GCRC) Seminar Series, On Methods in Clinical Research: Syphilis Pathogenesis: From the Bench Top to the Developing World and Back. UCHC, Tuesday, May 1, 2007.
33. Pediatric Grand Rounds, St. Francis Hospital and Medical Center, February, 2008. Update on Pediatric HIV.
34. Family Medicine Grand Rounds, St. Francis Hospital and Medical Center, March, 2008, Pediatric HIV, 27 years in the making.
35. Pediatric Grand Rounds, CCMC, “HIV testing in the office and school setting”. April, 2008.
36. Invited Speaker, Venereal Syphilis in Cali, Colombia. From the basic science laboratory to the streets of Cali, Colombia and back. Yale University Department of Pediatrics. November 4<sup>th</sup>, 2008.
37. Invited Speaker, Deciphering the Paradox of Secondary Syphilis Using a Translational Research Approach. Presented at the First CCMC/UCHC Research Day, Hartford, CT March 24, 2010.
38. Pediatric Grand Rounds, CCMC, March 15, 2011. Anatomy of the Cholera epidemic in rural Haiti.

### Regional Meetings (non hospital based)

1. Outpatient antibiotic treatment – Connecticut Children’s Medical Center - CME evening lecture series. Farmington, CT, October 1999.
2. Travel Medicine in Pediatrics. Connecticut Children’s Medical Center – CME evening lecture series. West Hartford, CT, January 2001.
3. Pediatric Pneumonia: What’s New in Diagnosis and Treatment? Pfizer Educational Dinner for Community Pediatricians, Hartford, February 2001.
4. Growing up with HIV (CME). Guest speaker. International panel. Farmington, CT, October 5, 2001.
5. Latino Leadership Summit on HIV/AIDS. Panelist, Risky Behaviors in Adolescents: What you don’t know can hurt you. November 15, 2002. East Hartford, CT
6. Invited Speaker. Optimizing Otitis Media Treatment (CME accredited). Mystic Marriott, March 19, 2003
7. Youth at Risk for HIV. Connecticut Department of Public Health sponsored HIV prevention lecture series (CME event). Presented in Groton, Stamford, Meriden/Middletown, Storrs, Hartford, and New Haven Connecticut. September and October, 2003.
8. Perinatal HIV – overview for MPH students – Epidemiology of Infectious Diseases. SUNY, Albany, School of Public Health. October 25, 2004.
9. Guest speaker. Adolescent HIV. Hartford Board of Education Yearly Meeting “Infectious Diseases in Youth”. Hartford, CT, May 12, 2005.
10. Guest speaker. HIV, STDs and Youth, Changing the Paradigm. HYHIL, CAETC, CCMC HIV program. Rensselaer at Hartford, June 16, 2005.
11. Guest speaker. Syphilis-HIV research in Latin America: Challenges and opportunities. Educational seminar hosted by the Society of Clinical Research Associates (SOCRA). Oct, 27, 2005. Hartford, Connecticut.
12. Visiting Scholar: HIV and Syphilis – How they fooled the immune system. Trinity College Summer Research Program Presentation. Hartford, CT, July 12, 2006.
13. Perinatal HIV the first 25 years– overview for MPH students – Epidemiology of Infectious Diseases. SUNY, Albany, School of Public Health. November 13, 2006.
14. The Hispanic Adolescent and HIV. Presented at the 2<sup>nd</sup> Connecticut Latino Council on HIV/AIDS meeting. Wallingford, CT May 10<sup>th</sup>, 2008.
15. *Borrelia burgdorferi* triggers phagocytosis dependent TLR2 independent signals in human monocytes. Presented at the October 2008, University of Connecticut, Department of Immunology, Graduate Retreat Program, Avery Point, Connecticut.

### National Meetings (USA)

1. Guest speaker. Strategies to improve adherence to anti-retroviral therapy in children. Presented at the yearly Pediatric AIDS Clinical Trials Meeting in Arlington, VA. July 21-24 2001
2. Guest speaker: Bayer corporation Cipro pediatric summer symposium. Pediatric Clinical Trial Experience: Physician, parent and child perspectives. San Diego, California, July 26-28, 2001
3. Invited Speaker. Advances in the treatment of acute otitis media. American Academy of Pediatrics Annual Meeting Satellite Symposium, Boston Marriott Copley Place, Boston, Massachusetts, October, 2002.
4. Guest speaker: Protocol PACTG 1051 update: Pharmacokinetic study of Tipranavir with Ritonavir in HIV-infected patients. Primary Therapy RAC Business Meeting, PACTG meeting, Baltimore Maryland, Dec 1-4, 2004.
5. Guest Lecturer, Pediatric HIV, presented at the Nicholas A. Rango HIV Clinical Scholars Retreat,– Albany, New York, May 4 & 5, 2005.
6. Guest Speaker, Perinatal HIV in the United States. Presented at the 25<sup>th</sup> US Colombian Medical Association Meeting, Miami Beach, Florida, July 28<sup>th</sup>, 2005
7. Guest speaker, Pediatric HIV – 25 years. HIV Clinical Care Symposium, Sponsored by Albany Medical College's Department of Medicine, Division of HIV Medicine. The Marriott, Albany, New York, Thursday, June 1<sup>st</sup>, 2006.
8. Guest speaker: 65<sup>th</sup> annual meeting of the Pediatric Travel Club, *T. pallidum* and HIV: How they took hostage the immune system. September 16, 2006, Mystic, CT.
9. Phagosomal signaling by *Borrelia burgdorferi*. Lyme Innate Immunity Mini-Symposium. University of Massachusetts Amherst, April 17, 2008 (Hosted by Dr. Juan Anguita).
10. Organizer and presenter: Congenital syphilis symposium – Focus on Latin America. State University of New York, School of Public Health, Albany, NY, May 1<sup>st</sup>, 2009.
11. Visiting Faculty, Secondary Syphilis translational research, Division of Immunology and Microbiology Faculty Rounds, New York Medical College, Valhalla, New York, May 12, 2010.
12. Visiting Faculty, Secondary Syphilis: Resolving the Paradox. Medical Grand Rounds presentation. George Washington University Hospital. Washington, D.C. November 11, 2010.

#### International Meetings

1. Sinusitis, therapeutic strategies, Congreso Nacional de Neumología, Puerto Rico, San Juan, Puerto Rico. November - 1998
2. HIV in children (perinatal HIV and treatment update), Congenital Infections, Guest speaker for the Corporación de lucha contra el SIDA's yearly congress, Cali, Colombia, South America April - 1999.

3. IV Colombian Infectious Diseases Association Congress, - Guest speaker: Otitis Media- State of the Art, and Perinatal HIV Update. Cartagena, Colombia, South America, June 2-5, 1999.
4. Guest speaker. Sinusitis, Therapeutic strategies, Samsung Medical Center, Seoul, Korea. Korean University Department of Pediatrics, Seoul, Korea, July 1999
5. Streptococcal Pharyngitis, Korean Head and Neck Surgery Society, Seoul, Korea, July 1999.
6. HIV update invited speaker, Guest speaker for the Corporación de lucha contra el SIDA's yearly congress, Cali, Colombia, South America, April, 2000.
7. Guest speaker at the Dominican Republic Perinatal Society Meeting (Meningitis, Perinatal HIV, and Congenital Infections). Santo Domingo, Dominican Republic, August 2000.
8. Adolescent HIV. Guest speaker for the Corporación de lucha contra el SIDA's yearly congress, Cali, Colombia, South America, April, 2001.
9. V Colombian Infectious Disease Association Congress – Guest speaker: (Sinusitis and Otitis Media update, Pediatric Infectious Disease Literature Update, HIV in adolescents, HIV resistance to HAART). Cartagena, Colombia, June 2001.
10. Guest speaker, (Kawasaki's disease, Pediatric pneumonia, and Pediatric HIV complications) Corporación de Lucha Contra el SIDA's yearly congress, Cali, Colombia, South America, March, 2002.
11. Invited speaker, (New Antibiotics in Neonatology and Perinatal Transmission of HIV – prevention strategies) VII Congress of the Dominican Republic's Perinatal Society, La Romana, Dominican Republic, August 24, 2002.
12. Guest speaker at GHESKIO, Syphilis and Lyme Disease Pathogenesis. Port-au-Prince Haiti, August, 2002.
13. Guest speaker, VII Colombian Infectious Disease Association Congress. Advances in Urinary Tract Infections in Children; Severe Perinatal Infections, Antibacterial Eradication and Therapeutic Success. Cartagena, Colombia, June 3-8, 2003.
14. Featured International Speaker (Otitis Media, Fever in Infants, and Perinatal Transmission of HIV). I Congreso de Medicos Generales del Suroccidente Colombiano (I Congress for General Practitioners in Southwestern Colombia). Sponsored by the Universidad del Cauca's Medical School, Popayán, Colombia, Oct 22-25<sup>th</sup>, 2003.
15. Guest speaker, (Otitis Media, Pediatric AIDS and Interactive Case Presentations), Corporación de Lucha Contra el SIDA's yearly meeting, Cali, Colombia. Received award for academic merit, March 2004.
16. Guest speaker, (Congenital syphilis, IV generation cephalosporins, and RSV bronchiolitis-evidenced based management), Corporación Pediátrica, Xth International Pediatric Infectious Diseases Meeting, Cali, Colombia, May, 2004.
17. International Speaker, Ecuadorian Society of Infectious Diseases Yearly Meeting, Guayaquil, Ecuador, July, 2004.

18. Guest speaker, (25 year history of perinatal HIV infection in the US, Early immunity in secondary syphilis – pathway to HIV-coinfection), Corporación de Lucha Contra el SIDA's yearly meeting, Cali, Colombia. March 2005.
19. Guest speaker, (Osteomyelitis in children, congenital syphilis, pediatric HIV and parenteral antibiotics in children), VII Colombian Infectious Disease Society Meeting, Medellín, Colombia, May 2005.
20. Guest speaker, (Adolescent HIV, HPV infections in adolescents, Tipranavir use in adults and children, Transfusion associated *Babesia microti*). Corporación de Lucha Contra el SIDA's yearly meeting, Cali, Colombia, April 2006.
21. Keynote speaker – Breast Feeding Controversies and Perinatal HIV Infection, VIII Colombian Infectious Diseases Society Meeting, Bogota, Colombia, May 2007.
22. Invited speaker – International Translational Research Environment: Challenges and Opportunities. 17<sup>th</sup> annual conference of the Society of Clinical Research Associates, Sept, 2008, Vancouver, Canada.
23. Guest speaker – XV international meeting of the Corporacion de Lucha Contra el SIDA. Cali, Colombia, April 2009.
24. Guest speaker – Latin American Society of Infectious Diseases Meeting. Cali, Colombia, August, 2010.